KLRS
Kalaris Therapeutics, Inc. - Common Stock (KLRS)
$70
About Kalaris Therapeutics, Inc. - Common Stock (KLRS)
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.
Details
Daily high
$2.90
Daily low
$2.51
Price at open
$2.90
52 Week High
$11.88
52 Week Low
$2.51
Market cap
67.8M
Dividend yield
-
Volume
235,896
Avg. volume
73,708
P/E ratio
-1.42
Kalaris Therapeutics, Inc. - Common Stock News
Details
Daily high
$2.90
Daily low
$2.51
Price at open
$2.90
52 Week High
$11.88
52 Week Low
$2.51
Market cap
67.8M
Dividend yield
-
Volume
235,896
Avg. volume
73,708
P/E ratio
-1.42